Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Breast Most cancers Consciousness Month protection spanned groundbreaking FDA approvals, survivorship challenges and improvements in breast reconstruction this October, emphasizing the continued...
October introduced a number of important updates in gastrointestinal most cancers analysis and drug growth, together with progress in rectal and gastric...
